Terumo has opened the recently completed manufacturing plant and expanded Ann Arbor headquarters in the state of Michigan. Terumo's operations have been part of the Southeastern (SE) Michigan medical device industry since the 1960s. The campus currently serves as the corporate headquarters for two Terumo US subsidiaries, Terumo Cardiovascular Systems and Terumo Heart.

As a recipient of a 2008 Michigan Economic Growth Authority (MEGA) Grant, Terumo was able to transfer research, development and manufacturing operations from its plant in Tustin, California to its Ann Arbor campus.

In the 18 months since receiving the grant, Terumo has nearly met the five-year hiring requirements by creating 63 new positions with additional positions expected in 2010. Terumo has also built a new chemistry lab, remodeled the existing buildings to suit the growth of the businesses, and added a new plant to one of the office buildings. In addition, Terumo Heart has expanded their office space, hired new employees, and created a new medical device manufacturing facility onsite.

Both the subsidiaries are focused on the research and development of world-class, life-saving medical device technology that benefits patient suffering from heart disease and serves the needs of the healthcare providers who treat them.

Mark Sutter, president and CEO of Terumo Cardiovascular Systems, said: “We are delighted that distinguished members of our state and local government and business leadership could join us today to celebrate our growth as evidenced by our new facility and manufacturing plant. Terumo shares a long, successful history with Ann Arbor and the Southeastern Michigan community. The MEGA grant has certainly increased our ability to drive current and future growth, which benefits us all.”

William Pinon, president and CEO of Terumo Heart, said: “At Terumo Heart, we’re focused on advancing the pivotal clinical trial that we hope will lead to FDA approval of our next-generation DuraHeart Left Ventricular Assist System, which is designed to provide sustained quality of life to patients with late-stage heart failure until a suitable organ transplant can be located. Our new manufacturing plant not only brings local prosperity, but allows us to produce a better product in a more efficient way.”